W
ith the diagnosis of vestibular schwannomas, the ability to prognosticate about the eventual outcome and disease control is challenging, given the complex set of circumstances in patients with recurrent and/or residual tumors. The present systematic review seeks to summarize the literature on these topics in order to provide clinical practice guidelines based on a robust systematic review of the literature, as well as to identify gaps in our knowledge and suggest avenues for future study.
ABBREVIATIONS: JGC, Joint Guidelines Committee; VEGF, vascular endothelial growth factor
METHODS
The task force group collaborated with a medical librarian to search for articles published from January 1, 1990 to December 31, 2014. Two electronic databases, PubMed and the Cochrane Central Register of Controlled Trials, were searched. Strategies for searching electronic databases were constructed using previously published search strategies to identify relevant studies. A total of 688 citations were manually reviewed by the team with specific inclusion and exclusion criteria as outlined below. Two independent reviewers screened the abstracts to determine those worthy of full-text review. Citations that considered adult patients focusing on surgical treatment of vestibular schwannomas were considered. The following inclusions and exclusions were then applied: (1) investigated patients suspected of having vestibular schwannomas, (2) patients ≥ 18 yr of age, (3) was of humans, (4) published between January 1, 1990 and December 31, 2014, (5) quantitatively presented results, (6) was not an in Vitro study (for novel molecular markers, in Vitro studies were included on patient samples), (7) was not a biomechanical study, (8) was not performed on cadavers, (9) was published in English, (10) was not a meeting abstract, editorial, letter, or a commentary, (11) studies may include mixed pathology; however, the data pertaining to vestibular schwannomas were abstractable from the paper, and (12) greater than 5 patients or patient samples. The articles deemed relevant for full-text review were then reviewed, and the study design, topic evaluated, and conclusions were extracted. The items in the above-mentioned inclusion and exclusion criteria were applied prior to inclusion in the final data set. For some questions, it became apparent that the data in the full-text articles were not able to provide meaningful support for any form of recommendation, and these questions were simplified or excluded. The selected studies were classified according to criteria for evidence on prognosis as detailed in the Joint Guidelines Committee (JGC) Guideline Development Methodology (https://www.cns.org/guidelines/guideline-procedurespolicies/guideline-development-methodology).
RESULTS
The literature on these topics generally was sparse and did not allow for any meaningful recommendations based on the data. Specifically, we found only a few small, retrospective studies about the prognostic impact of mitotic figures, extent of Antoni A vs B pathology, Ki-67, PCNA (proliferating cell nuclear antigen), of VEGF (vascular endothelial growth factor) expression, and almost no other literature about other pathological features. We cannot make recommendations about any of these variables based on these findings.
DISCUSSION AND CONCLUSION
Based on the literature obtained from these literature searches, one can conclude that there is much yet to be gleaned from the histologic, immunohistochemical, and molecular marker status of vestibular schwannomas in terms of determining functional prognosis, risk of recurrence, and response to surgical or nonsurgical therapy. The exact utility of KI-67 and proliferating cell nuclear antigen labeling indices in predicting future recurrence after surgery is essentially unknown and is in need of future study. VEGF staining is an interesting area of future investigation as its exact utility is unclear at present. As mentioned above, it would be very helpful to know whether or not tumors that behaved badly express more VEGF. Also, are vestibular schwannomas that express VEGF at higher levels deserving of different treatment? With the advent of reliable tumor banking and electronic database availability, one can imagine both of these questions could be addressed in a retrospective fashion. With this data in hand, a prospective study to validate whatever suspicions arise from those findings could then be planned.
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Disclaimer of Liability
This clinical systematic review and evidence-based guideline was developed by a multidisciplinary physician volunteer task force and serves as an educational tool designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
